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Abstract 
Background: Lentiviral vectors (LV) are widely used for various gene transfer or gene therapy applications. The 
effects of LV on target cells are expected to be limited to gene delivery. Yet, human hematopoietic CD34+ cells 
respond to functional LVs as well as several types of non-integrating LVs by genome-wide DNA methylation changes.
Results: A new algorithm for the analysis of 450K Illumina data showed that these changes were marked by de novo 
methylation. The same 4126 cytosines located in islands corresponding to 1059 genes were systematically methyl-
ated. This effect required cellular entry of the viral particle in the cells but not the genomic integration of the vector 
cassette. Some LV preparations induced only mild sporadic changes while others had strong effects suggesting that 
LV batch heterogeneity may be related to the extent of the epigenetic response.
Conclusion: These findings identify a previously uncharacterized but consistent cellular response to viral compo-
nents and provide a novel example of environmentally modified epigenome.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background
The maintenance of a coordinated gene expression pat-
tern is largely dependent on the chromatin organization 
in the cell nucleus. Epigenetic mechanisms such as DNA 
methylation play a key role in determining chromatin 
structure. In addition, these mechanisms represent an 
interface between environment and genome function [1].
Lentiviral vectors (LV) are convenient tools to achieve 
stable gene transfer in target cells for research, engineer-
ing or clinical applications such as gene therapy studies 
[2]. Integration-defective LV have also been designed 
for various transient gene delivery applications [3]. It is 
presumed that for all such uses, LV would not modify 
the function of transduced cells other than by effects of 
the transgene itself. Nonetheless several types of cellular 
responses have been caused by LV independently of the 
transgene. The proviral DNA was found to trigger tran-
sient innate immune responses in dendritic cells [4] and 
in mice [5] and its genomic insertion may potentially 
cause genotoxicity [2].
Recent studies have clearly demonstrated that LV can 
have a strong and long lasting epigenetic effects on trans-
duced cells. For example, LV-s alone have been reported 
to epigenetically reprogram fibroblasts in culture inde-
pendently of other external factors [6, 7]. We recently 
provided the first direct evidence that the in vitro trans-
duction of hematopoietic stem and progenitor cells 
(HSC) with LVs induces DNA methylation of CpG nucle-
otides within 24 h after the first contact between the cells 
and vectors [8]. The epigenetic effects of LV have not 
been characterized in depth and it is not known if they 
are caused by the lentiviral provirus or by the viral com-
ponents before integration of the viral genome.
The epigenetic alterations in HSC seem particu-
larly important to assess given that self-renewal and 
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differentiation of HSC are highly dependent on epige-
netic mechanisms [9–13]. A potential impact of LV-
induced epigenetic effects has to be considered when 
LV-s are used in gene therapy protocols based on LV-
mediated gene transfer into patient-autologous CD34+ 
HSC to treat genetic diseases [2]. It is therefore impor-
tant to investigate the exact nature of LV induced epige-
netic changes in human HSCs in conditions relevant to 
gene therapy protocols.
The present study was conducted to determine the 
distribution of DNA methylation changes in the cellu-
lar genome in response to LV and the relation between 
them and the integration of the vector genome. We show 
that in addition to randomly occurring modifications a 
defined set of CpG islands associated to more than 1000 
genes are systematically methylated. The DNA methyla-
tion changes occurred independently of the integration 
of the viral genome and only required cellular entry of 
the viral particle. Importantly, only some vector batches 
induce reproducible changes, other batches of the same 
vector produce only sporadic effects.
Results
The Infinium Human Methylation 450K BeadChip (Illu-
mina) provides a high resolution quantitative assess-
ment of the CpG methylation level of relevant genomic 
regions. A major difficulty when comparing two meth-
ylation profiles with this method is to separate small but 
“true” changes from the background noise. Noise filtering 
can be performed intuitively by the use of pre-determine 
fixed threshold above which methylation changes are 
considered real. However, this traditional approach also 
eliminates small “true” changes. To overcome this diffi-
culty, we have established an improved method for the 
detection of small methylation changes based on their 
repeated occurrence.
New method for the analysis of the methylation changes 
using the Infinium 450K array
A new algorithm called “double average technique” 
(DAT) was designed to identify very small, but repro-
ducible differences between two series of samples after 
normalization of the raw data (see the workflow of the 
data analysis and representation on Fig.  1). This highly 
sensitive method identifies only reproducible differences 
in cytosine methylation level present in all samples com-
pared to their reference controls. Sporadic differences are 
filtered. The method is implemented on triplicate experi-
ments requiring the comparison of 3 samples with 3 cor-
responding controls. Thus, after hybridization on the 
450K bead chip, 6 β-values are obtained for each CpG site 
tested. The sliding average (<β>) of the β-values of 3 con-
secutive CpG-s for each sample (t1, t2 and t3) and for each 
of the corresponding control (c1, c2 and c3) are calculated. 
The methylation of a given CpG site is considered to be 
different between the sample and control triplicates if 
all three values of the sliding averages of the samples are 
above (t1, t2, t3 ≥ increased methylation) or below (t1, t2, 
t3 ≤ decreased methylation) of the arithmetic average of 
the 6 <β>-values [(t1 + t2 + t3 + c1 + c2 + c3)/6] of the 
samples and controls. This constraint confers to the algo-
rithm a very high stringency and allows the identification 
of all CpG sites with increased or decreased methylation 
independently of the extent of the difference and with-
out applying the same fixed threshold to all CpG-s on the 
chip. The list of these CpG-s provides information on the 
total number of modified cytosines, their position in the 
genome and the extent of the increase or decrease of the 
methylation at each site.
Global assessment of the difference between the con-
trol and experimental triplicates is provided by three 
parameters. The first parameter (N) is the total number 
of CpG-s with altered methylation compared to controls. 
The second parameter shows the clustering of methyla-
tion changes in the genome. The value of this parameter 
is equal to the chi2 when comparing the distribution of 
the modified CpG-s to the theoretical random distribu-
tion of the same number of sites. The third parameter is 
the median difference between the β-values (delta-β) of 
the experimental and control triplicates for increased 
or decreased CpG-s. The three parameters were calcu-
lated separately for CpG-s with increased and decreased 
methylation.
DNA methylation in CD34+ cells increases in response 
to LV transduction
First, we sought to determine if the previously observed 
changes in umbilical cord blood CD34+ cells using a 
Infinium 27K chip [8] could be confirmed with the Infin-
ium 450K chip on a broader set of CpGs in CD34+ cells 
obtained from apheresed adult donors, a material more 
relevant to clinical use. In a pilot study we compared 
one of the samples examined in our previous report [8] 
with a DNA sample isolated from LV transduced CD34+ 
cells isolated from cytokine-mobilized human periph-
eral blood. We confirmed that CpG methylation changes 
in the cellular genome were induced in response to LV 
transduction in the CD34+ cells isolated from the two 
different sources (not shown). In all subsequent experi-
ments we used CD34+ cells obtained from apheresed 
blood of adult individuals.
We then transduced CD34+ cells of 12 different 
donors using multiple batches of vector (Table  1) to 
examine the methylation profile of their genomic DNA 
using Infinium 450K chip runs. The characteristics of the 
vectors used and their potency is reported in Additional 
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Fig. 1 Workflow of data analysis and representation. The normalized β-values of triplicate samples and their corresponding controls are analyzed 
using the DAT algorithm as described in the text. a First, a moving average <β> is calculated for each CpG position in each sample and control. 
The average of all six sample <β> values is calculated ≪β≫. b The methylation level of a given CpG is considered as “increased” in the samples 
compared to controls if all the <β> values are higher then ≪β≫ or decreased if lower then ≪β≫. The above operation is repeated for all CpG-s 
analyzed by the Illumina chip. c Three parameters are calculated on the basis of the lists of “increased” and “decreased” CpG-s: (1) the total number 
of CpG-s (N); (2) chi2 calculated on the basis of the observed distribution of the CpG cluster sizes compared to the simulated random distribution of 
cluster sizes obtained with an identical number of CpG sites; (3) the median delta-β value of all the N CpG-s
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file 1. All 5 batches of LVs tested encoded GFP and were 
produced by transient transfection using second or third 
generation constructs. Three batches were concentrated 
by ultracentrifugation (LV1–LV3). In order to investi-
gate the potential contribution of product contaminants, 
two batches (LV4–LV5) were purified and concentrated 
by ion exchange chromatography followed by ultrafiltra-
tion and gel filtration, a method that extensively removes 
protein and DNA contaminants from the vector prepa-
ration [14]. We analyzed the effects of several batches of 
non-integrating LV which were generated by completely 
removing the vector system HIV-1 integrase as a result 
of a stop codon in the pol gene (dINT) or by omitting the 
transfer plasmid leading to so-called “genome-empty” 
particles (dGEN). Two batches each of dINT and dGEN 
preparations were tested and verified to be unable to 
express a transgene and to integrate (Table  1). In addi-
tion, we also tested in these same experiments 3 batches 
of vectors unable to infect cells due to the omission of the 
envelope glycoprotein plasmid in the production pro-
cess (dENV). All such defective vectors, except for the 
genome-deficient (dGEN) vectors included a transgene 
cassette coding for the green fluorescent protein (GFP). 
All were concentrated by ultracentrifugation (Additional 
file  1). They were tested in parallel with the fully func-
tional LV using comparable amounts of particles on the 
basis of physical titer (Additional file 1).
Using a similar transduction protocol as described 
earlier [8], CD34+ cells were stimulated with early-act-
ing cytokines for 20  h, cultured with LV (2 consecutive 
hits) during 24  h before genomic DNA was prepared 
for methylation analysis. Table  1 shows that all batches 
of functional LV resulted in similar transduction levels 
based on measures of the average vector copy number 
per cell (vcn) integrated and based on the percentage of 
cells expressing the GFP transgene after a short addi-
tional culture. No transduction was observed with the 
various defective vectors. Controls were set-up with cells 
from the same donors that were tested in parallel, cul-
tured identically to the test cultures but without adding 
LV to the culture medium.
The genomic DNA from the infected cells was 
extracted, bisulfite-converted, subjected to Infinium 450K 
array hybridization and analyzed using the DAT method. 
Volcano plot representation of the median and maximal 
delta-β values of CpG-s with increased and decreased 
methylation in triplicate samples of some representa-
tive experiments are shown on Fig. 2a. We calculated the 
three parameters (Fig.  1) that characterized the differ-
ences between the sample triplicates and their matched 
controls. In order to compare the effects observed with 
different vector preparations, we performed hierarchical 
clustering of the results. Data obtained for increased and 
decreased methylation were submitted to independent 
analysis (Fig. 2b).
When increased methylation is considered, the vari-
ous LV-s segregated in two different clusters (Fig.  2b). 
The first cluster (“high”) included 2 of the 3 LV batches 
produced by ultracentrifugation and all of the inte-
grase-deficient vectors and genome-deficient vector 
batches (Table 1). In addition to the relatively high num-
ber of methylated CpG-s, the distinguishing feature of 
Table 1 Effects of different batches of vectors and particles on CD34+ cells
a See Fig. 2b
Integrating lentiviral vector LV Integrase-deficient 
particles dINT
Transgene construct- 
deficient particles 
dGEN
Envelope-deficient particles 
dENV
Batches tested LV1 LV2 LV3 LV4 LV5 dINT1 dINT2 dGEN1 dGEN2 dENV1 dENV2 dENV3
Number of times 
tested indepen-
dently
2 1 2 2 1 2 1 2 1 2 1 1
Number of different 
CD34+ cell donors 
tested
6 3 6 6 3 6 3 6 3 6 3 3
Average transduc-
tion efficiency (% 
GFP + cells ± SD) 
(range)
54 ± 8 
(41–64)
52 ± 13 
(39–7)
59 ± 6 
(47–72)
57 ± 14 
(39–85)
41 ± 7 
(31–47)
0.1 ± 0.1 
(0–0.3)
0.2 ± 0.2 
(0–0.7)
0.1 ± 0.1 
(0–0.1)
0 ± 0 
(0–0.1)
0 ± 0 
(0–0.3)
0 ± 0 
(0–0.1)
0 ± 0 
(0–0.1)
Average vector copy 
number per cell 
(VCN ± SD)
3.3 ± 1.1 NT 2.6 ± 1.3 0.4 ± 0.02 0.7 ± 0.1 0 ± 0 0.1 ± 0.1 0 ± 0 0 ± 0 0 ± 0 0 ± 0 0 ± 0
Increased methyla-
tion cluster effecta
Low, Low High High, High Low, Low Low High, High High Low, High High Low, Low Low Low
Decreased methyla-
tion cluster effecta
Low, Low Low Low, Low Low, Low Low Low, High Low Low, High Low Low, Low Low Low
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methylation profiles in this group was the strong non-
random distribution in the genome (high χ2) and rela-
tively high proportion of the cells harboring methylation 
at these sites (high delta-β). The second cluster (“low”) 
included the 2 chromatography-purified and one ultra-
centrifuged batches of LV and all of the dENV batches. 
The “low” group also contained the background control 
of the experiments (Ctrl) that consists in a comparison 
between two sets of uninfected cell triplicates. The “low” 
group was characterized by higher dispersion of the 
modified CpG-s (lower χ2) and lower frequency in the 
cell population (lower delta-β). Repeated testing of the 
same LV batches provided the same categorization of 
their effects as seen for LV1, LV3, LV4.
Ctrl
LV1a
dENV2
LV4b
dENV3
LV1b
LV5
dENV1
dENV1
dGEN
LV4a
dGEN
dGEN2
dINT2
LV2
LV3b
LV3a
dINT1a
dINT1b
∆
Ctrl
dENV3
LV1a
LV4b
dENV2
dGEN1a
LV5
dENV1a
LV1b
dENV1b
LV4a
dGEN2
LV3b
dINT2
dINT1a
LV2
LV3a
dINT1b
dGEN1b
∆
a
b
Fig. 2 Analysis of DNA methylation changes. Analyses of 4 different chip runs (a, b, c, d) testing a total of 12 different batches of vector annotated 
accordingly (i.e. dENV1a and dENV1b indicates a repeat testing of dENV1 batch on chip a and chip b). a Volcano plots of representative experiments. 
From left to right: methylation differences observed in cells infected with an integrative lentiviral vector showing a high effect (LV2), integrase-defi-
cient particles (dINT2), genome-deficient (dGEN2) and envelope-deficient (dENV1) particles as compared to control cells cultured but without any 
vector. The last plot on the right represents a control triplicate compared to another control triplicate (as in bottom line of b). Each point on a volcano 
plot represents the maximal delta-β value of a CpG site in a given triplicate as a function of the median of the three delta-β values of that triplicate. 
Only the CpG-s identified as displaying altered methylation between the samples and their corresponding controls are shown. Points represent-
ing CpG sites with increased and decreased methylation are displayed on the right and left sites of the plot. Note the higher number of points and 
higher median and maximal delta-β values with increased methylation in the first three samples. b Hierarchical classification of the experimental 
conditions depending on the extent of the increase (left) or the decrease (right) of the genomic DNA methylation in CD34+ cells. The classification 
was done using the three parameters indicated in the table: number of changed CpGs (N), chi2 of genomic distribution and median delta-β
Page 6 of 10Aranyi et al. Epigenetics & Chromatin  (2016) 9:29 
Cluster analysis was also performed on the param-
eters for decreased CpG methylation. No clear segrega-
tion into two groups can be observed. The two batches 
(dGEN1 and dINT1) clustered separately from the others 
showing “high” effects on decreased methylation but this 
was not reproduced in a second independent experiment 
(Fig.  2b). Overall, the number of demethylated CpG-s 
and their incidence was often lower than the corre-
sponding numbers for increased methylation in the same 
experimental conditions. This suggests that the cellular 
response to the different vectors involves principally de-
novo methylation at a variable number of CpG sites and 
to variable extent. Nevertheless, some demethylation may 
also occur. The methylation changes are clearly unrelated 
to the integration of the viral genome in the host genome, 
because non-integrative vectors also induce methylation.
The genomic localization of the changes shows recurrent 
methylation pattern
To further characterize the DNA methylation changes, 
we compared the lists of CpG-s with increased and 
decreased methylation in the “high” and “low” clusters. 
The lists in the “low” cluster did not share common CpG-
s. Similarly, the lists of CpG-s with decreased methyla-
tion did not overlap significantly with one another. By 
contrast, the comparison of the 8 lists of CpG-s with 
increased methylation obtained in the “high” group 
revealed a substantial overlap. The methylation of 4126 
CpG sites became higher in all 8 conditions that involved 
different vector types (Fig. 3), but also CD34+ cells from 
different donors (Table 1). The probability to get such a 
high number of identical changes fortuitously is essen-
tially zero (p < 10−60). These sites represent 7–20 % of all 
CpG-s with increased methylation that were detected in 
the various conditions and almost 1 % of all sites present 
on the Illumina array. This high number of recurrently 
de novo methylated CpG-s (commonly-modified CpG-s, 
CM-CpG) in a subset of genes suggests that the expo-
sure of the cells to vector particles triggers the action of a 
common mechanism.
The majority (86 %) of the 4126 common modified CpG 
sites were found in CpG islands (CGI) (Fig.  4) in gene 
promoters, 5′UTRs, 1st exons and enhancers of 1059 
genes (Additional file  2). The CpG-s in island “shores”, 
“shelves” or at non-assigned positions were strikingly 
underrepresented on our list (Fig.  4). The preferential 
localization of the CM-CpG-s to islands explains the high 
χ2 score obtained when the clustered distribution of the 
modifications were calculated (Fig. 2b).
We compared the list of the 1059 genes with that of 
genes reported to be expressed in CD34+ cells [15]. 
Of the 928 genes associated with CM-CpG-s and rep-
resented on the chip only 265 genes were expressed 
and 663 were silent in pre-activated CD34+ cells (the 
remaining 131 genes were not interrogated by the chip). 
This is significantly higher than the proportion of the 
non-expressed genes in the dataset (529 genes expressed 
versus 399 silent genes).
The integration of the HIV-1-derived LV-s in the host 
cell’s genome is not random. Although the DNA methyla-
tion changes occur independently of the integration, it is 
possible that the potential integration sites and the loca-
tion of the CM-CpG-s are somehow related. To clarify 
this we calculated the distances between each CM-CpG 
and the position of closest integration site in a dataset of 
more than 30,000 LV integration sites [15]. The distribu-
tion of the distances was found to be random, showing 
that the sites targeted by the methylation changes and by 
the integration are unrelated.
In order to determine if these genes belong to specific 
functional categories, we have verified their functional 
ontology annotation using the DAVID tool. No signifi-
cant enrichment was found. The 5 best represented func-
tional categories of genes were involved in: regulation 
of transcription (GO:0045449; 224 genes, p < 7 × 10−14, 
1.6 fold enrichment), regulation of RNA metabolic pro-
cesses (GO:0051252; 185 genes, p < 1.1 × 10−19, 1.9 fold 
enrichment), regulation of transcription DNA depend-
ent (GO:0006355; 184 genes, p  <  2.4  ×  10−19, 1.9 fold 
enrichment), positive regulation of biosynthetic pro-
cesses (GO:0009891, p  <  9.6  ×  10−11, 2.1 fold enrich-
ment) and neuron differentiation (GO:0030182, 77 genes, 
p  <  4.7 ×  10−20, 3.2 fold enrichment). Although any of 
Fig. 3 Venn diagram indicating the overlap between the eight differ-
ent conditions identified as having “high” effect on increased meth-
ylation. 4126 is the number of CM-CpG sites. The different conditions 
were A dINT1b (76382 CpG-s); B dINTa (20337 CpG-s); C LV3a (29123 
CpG-s); D LV3b (24818 CpG-s); E LV2 (29007 CpG-s); F dINT2 (57624 
CpG-s); G dGEN2 (31059 CpG-s); H dGEN1b (20566 CpG-s), as defined 
on the Table 1
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these categories showed significant enrichment, exam-
ples of genes found on the list are known to impact the 
normal or pathological cell differentiation: genes coding 
for zinc finger-, homeobox-containing transcription fac-
tors, nuclear receptors,—de novo DNA methyl trans-
ferase Dnmt3A and SWI/SNF a chromatin structure 
modifying enzyme. Other genes on the list are implicated 
specifically in hematopoietic differentiation (e.g. GATA2, 
VENTX or CEBPd) or have important immunologic 
function (CD8a and b or BCL2L11). We also compared 
our gene list to the comprehensive cancer gene list estab-
lished on the basis of observations from several labo-
ratories (http://www.bushmanlab.org/links/genelists). 
Importantly, the two lists contained 152 genes in com-
mon. These observations clearly show that the methyl-
ated CM-CpG islands are not targeted for the biological 
function of the genes they regulate. Nevertheless, if the 
expression of these genes is perturbed by the methyla-
tion reprogramming, the functional consequences may 
be important and the differentiation of the cells may be 
impacted.
Discussion
The purpose of the present study was twofold: to char-
acterize the genomic distribution of the DNA meth-
ylation changes in response to LV and to investigate if 
these changes are related to the genomic integration of 
the vector. To this end, a stringent algorithm was devel-
oped to detect reproducible and clustered methylation 
changes. The main finding in this paper is that CD34+ 
cells respond to some batches of LV by systematic de 
novo methylation of the same CpG islands in the prox-
imity of 1059 genes. The highly significant reproducibil-
ity of the “strong” effect in cells of 24 different donors 
and 8 different vector batches underscores the impor-
tance of the cellular response. However, other LV batches 
induce a milder “low” effect characterized by fewer 
modified CpG-s in dispersed genomic locations without 
recurrent changes and in a smaller proportion of cells. 
These observations can be understood as a heterogene-
ous manifestation of the same type of cellular response: 
some LV batches pass the threshold and induce “high” 
cellular reaction, while others stay below and elicit only 
a mild ‘low” effect. Although the precise mechanisms for 
the establishment of de novo methylation patterns in the 
genome are not yet elucidated [16–18], rapid changes are 
possible due to the highly dynamic maintenance of the 
DNA methylation [16, 18]. Various types of environmen-
tal stress are known to generate epigenetic response. For 
example, physiological stress related to under- or over-
nutrition during fetal life is associated with global shifts 
towards DNA hypermethylation in CD34+ cells [19]. 
Stress related to in vitro culture of HSC-s also increases 
the methylation at specific sites in correlation with the 
loss of differentiation potential [13]. Our observations 
provide a new example of environmental stimulus or 
stress causing essentially de novo methylation.
An important issue is to evaluate the functional conse-
quences of this response. In this respect, we observe that 
genes that become methylated belong to a wide range of 
functional pathways and not to specific categories. There-
fore, these genes are probably not targeted for their func-
tion, but most likely because of their genomic location. 
Most of them are not expressed at the stage when the 
modification occurs, which reinforces this hypothesis. 
If the de novo methylation is maintained and perturbs 
gene expression at a later stage, the potential phenotypic 
effects are expected to be highly variable. This will make 
their study particularly difficult in future investigations.
The induced methylation changes were clearly inde-
pendent of the integration of the vector genome in the 
cellular DNA and were not caused by proviral DNA 
because both the non-integrative dINT and dGEN vec-
tors had the same effect. No difference in potency for 
CD34+ transduction or titer could distinguish the LV 
with “high” or “low” effects. Furthermore, the commonly 
a b
Fig. 4 Genomic localization of the CM-CpG-s. a Distribution of all CpG-s interrogated by the array according to their sequence context as provided 
by the manufacturer. b Sequence environment of the CM-CpG-s
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methylated positions did not colocalize in a statistically 
significant manner with LV genomic integration sites 
reported in CD34+ cells by others [15]. We think that the 
observed changes represent an active cellular response 
to some vector components, but the identity of the trig-
ger remains unknown. The HIV integrase is required for 
the steps of reverse transcription, for the formation of the 
preintegration complex and mediates genomic insertion 
by tethering the preintegration complex to the host cell 
chromatin and associated factors [20]. dINT particles 
which completely lack integrase due to a stop codon in 
the pol gene sequence exerted a strong DNA methyla-
tion effect on HSC which is therefore independent of any 
of all these steps described. The effect is also independ-
ent the accumulation of episomal LTR-circles which do 
not occur here. In some models, LV enhance chromatin 
remodelling and nuclear reprogramming via the stimula-
tion of TLR3 pathway [6, 7]. It is unlikely that TLR3 is 
involved in our system, as double-stranded viral RNA 
that classically triggers TLR3 is not be produced sig-
nificantly by dINT and dGEN vectors. Whereas we can 
exclude that the DNA methylation is caused by the inte-
gration of LV or by the provirus, there are other possibili-
ties to consider based on the requirement for cell entry 
to generate the “high” cellular response. A single viral 
protein can cause genome-wide epigenetic changes as 
exemplified by adenovirus E1A [21, 22]. One possibility 
is that a minimal concentration of a viral component is 
necessary to induce the effect. A role of the VSVg enve-
lope protein can be envisioned. VSVg is present on all 
LV tested even those with “low” effects but the number 
of VSVg molecules per particle are known to vary from 
600 to 2200 per virion depending on the batches [23] 
and this could explain the variability of effects between 
LV batches. VSVg has been reported to constitute tubu-
lovesicules in LV preparations that entrap plasmid DNA 
and induce TLR9-mediated innate immune responses in 
target cells [24]. In such case, standardized methods and 
the inclusion of a purification step should homogenize 
VSVg quality and quantity on LV and may be important 
to reduce a DNA methylation effect. Indeed, standard-
ized LV preparations purified using ion exchange chro-
matography systematically induced “low” responses. 
Routine measurements of VSVg on LV batches will have 
to be developed to monitor this effect.
Another possible explanation is that the entry of large 
amounts of lentiviral vector components with non-inte-
grative particles triggers the cellular response. All vector 
preparations, even infectious LV batches are heterogene-
ous, they contain varying levels of lentiviral protein com-
ponents such as reverse transcriptase [23] and include 
no more than 1  % of infectious particles when com-
paring infectious and physical titers. Such inter-batch 
differences are not detected by infectivity measurements 
(Additional file 1). These non-integrative particles, when 
introduced in the cell, may trigger DNA methylation 
changes, as is observed with the dINT or dGEN. Addi-
tional studies will be needed to further address this point.
Altogether, our observations strongly suggest that 
LV batch quality is important, can be optimized at the 
upstream stages and may have a major impact on the 
transduced cells. Further studies are needed to develop 
quality control procedures to assess the DNA methyla-
tion effects of different preparations and to ensure that 
only LV with “low” properties would be used to trans-
duce HSC.
LV-s are increasingly popular as gene transfer tools in 
the everyday laboratory practice, but also in therapeutic 
strategies where gene transfer is required. Integration-
defective LV are also frequently preferred when transient 
expression of the transgene is required as, for example, 
in genome editing using CRISPR/Cas technology. Our 
observations which were made in clinically-relevant 
conditions (using apheresed CD34+ cells, the same 
cytokines and medium as used in clinical trials [25] and 
purified LV) point to the necessity of further investigat-
ing the mechanisms leading to the epigenetic changes. 
Understanding these mechanisms could open the way for 
further improving the safety of LV-s.
Conclusions
Using a sensitive pipeline for data analysis we identi-
fied a previously uncharacterized but consistent cellular 
response to viral components that involves a systematic 
de novo methylation of more than 4000 CpG-s associated 
with 1059 different genes in the genome. These observa-
tions provide a novel example of environmental stress 
modified epigenome.
Methods
Cell culture
Human mobilized peripheral blood cells were obtained 
with informed consent according to international ethi-
cal principles and according to the French national 
bioethic law (no 2011-814). The study no DC-2012-1655 
was approved by the French Ministry of Research and 
Higher Education-Bioethics office in September 2012. 
The anonymous samples were provided to us by accred-
ited laboratories including a biological resource center 
(MYOBANK-AFM in Paris (http://www.biobanques.
eu/ code BB-0033-00012), the French blood bank (EFS) 
(Hospital Henri Mondor, Créteil), the cell therapy labo-
ratories of Gustave Roussy Institute (Villejuif, France) or 
University Hospital Center of Amiens (Amiens, France). 
The CD34+ haematopoietic stem cell fraction was puri-
fied by Ficoll gradient centrifugation and magnetic bead 
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cell sorting according to the manufacturer’s instructions 
(Miltenyi). Purified cells were systematically analyzed by 
FACS and the CD34+ population was always >95 %. In 
total 12 purified samples from 12 different donors were 
used in the present study.
LV transduction
CD34+ cells were transduced as described previously [8]. 
Briefly, after purification 1 × 106 cells were pre-activated 
overnight at 37  °C in X-VIVO culture medium, sup-
plemented with antibiotics and cytokines (Flt3-ligand 
(300  ng/ml), stem cell factor (300  ng/ml), trombopoi-
etin (100  ng/ml) and IL3 (20  ng/ml). Transduction was 
performed in the presence of 4 μg/ml protamine sulfate 
(Sigma) with 5 ×  107  IG/ml (infectious genome) LV or 
equivalent amounts of p24 as specified in Additional 
file  1. A 2nd round of transduction was performed in 
the same conditions 6 h later. Transduction reaction was 
stopped 24  h after the beginning of the first round of 
transfection and cells were collected. After washing the 
cells a small fraction was put back to culture in preacti-
vating culture supplemented with 10 % SVF and transfec-
tion efficiency was verified 8 days later by FACS of GFP+ 
cells. Integrated vector copy number was determined at 
the same time on the same fraction by qPCR.
Lentiviral vectors
HIV-1 derived lentiviral vectors (LV) expressing eGFP 
under the control of the human PGK promoter and pseu-
dotyped with VSVg using a 3- or 4-plasmid system as 
indicated in Additional file 1 were produced by transient 
transfection of 293T cells. The 3-plasmid system used 
the p8.74 plasmid coding for HIV-1 gag pol rev tat acces-
sory genes. The 4-plasmid system used the pKLgagpol 
and pKRev plasmids. The culture medium was collected, 
concentrated by ultracentrifugation or chromatography 
and aliquots were stored at −80  °C. The chromatogra-
phy-purified preparations were produced as described 
[14]. Vector titers were determined as infectious genome/
ml (IG/ml) by qPCR after infection of HCT116 cells or 
as physical titers based on measured of P24 content by 
ELISA. Several deficient vectors were used in this study 
in addition to LV. dENV and dGEN vectors were respec-
tively produced by transient transfection as above omit-
ting the VSV-G encoding plasmid or the transfer plasmid 
encoding for eGFP. dINT particles were obtained by using 
the p8.74-INTSTOP plasmid in which a stop codon muta-
tion was introduced in the pol gene. Titers of dINT, dGEN 
and dENV particles was determined by P24 content.
Array based DNA methylation profiling and data analysis
LV transfection of the cells was followed by genomic 
DNA extraction. From each sample 500  ng genomic 
DNA was bisulfite treated using EZ DNA methylation kit 
and submitted to hybridization to the Infinium Human 
Mehtylation 450K BeadChip (Illumina) according to the 
manufacturer’s instruction. Results of the methylation 
assay were expressed as β values (ranging between 0—
non-methylated, and 1—methylated) for each individ-
ual CpG present on the array. Raw data were extracted 
and normalized using Genome Studio. Only non-poly-
morphic CpG-s located on somatic chromosomes were 
considered. (The data are available under GEO acces-
sion number: GSE72867). We used the DAT algorithm 
to score individual sites for their methylation status. 
The DAT algorithm was implemented in “R”. The genes 
assigned to the CpGs were identified according to the 
array’s annotation. Functional annotation of the genes 
was performed using the online DAVID Functional anno-
tation tool (http://www.david.abcc.ncifcrf.gov).
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